Topoisomerase inhibitors

9,223views

Topoisomerase inhibitors

RHS

RHS

Viral structure and functions
Rhinovirus
Adenovirus
Influenza virus
Human parainfluenza viruses
Respiratory syncytial virus
Staphylococcus aureus
Streptococcus viridans
Streptococcus pyogenes (Group A Strep)
Streptococcus pneumoniae
Corynebacterium diphtheriae (Diphtheria)
Enterococcus
Upper respiratory tract infection
Allergic rhinitis
Bacillus anthracis (Anthrax)
Nocardia
Enterobacter
Yersinia enterocolitica
Pseudomonas aeruginosa
Klebsiella pneumoniae
Legionella pneumophila (Legionnaires disease and Pontiac fever)
Bacteroides fragilis
Yersinia pestis (Plague)
Moraxella catarrhalis
Francisella tularensis (Tularemia)
Bordetella pertussis (Whooping cough)
Haemophilus influenzae
Pasteurella multocida
Mycobacterium tuberculosis (Tuberculosis)
Mycobacterium leprae
Mycobacterium avium complex (NORD)
Mycoplasma pneumoniae
Chlamydia pneumoniae
Coxiella burnetii (Q fever)
Epstein-Barr virus (Infectious mononucleosis)
Human herpesvirus 6 (Roseola)
Human herpesvirus 8 (Kaposi sarcoma)
Parvovirus B19
Mumps virus
Measles virus
Zika virus
Rubella virus
Candida
Plasmodium species (Malaria)
Asthma: Clinical
Pneumonia
Pneumonia: Pathology review
Respiratory distress syndrome: Pathology review
Restrictive lung diseases
Restrictive lung diseases: Pathology review
Sarcoidosis
Hypersensitivity pneumonitis
Obstructive lung diseases: Pathology review
Tuberculosis: Pathology review
Type IV hypersensitivity
Bartonella henselae (Cat-scratch disease and Bacillary angiomatosis)
Sinusitis
Laryngitis
Retropharyngeal and peritonsillar abscesses
Bacterial epiglottitis
Congenital pulmonary airway malformation
Acute respiratory distress syndrome
Emphysema
Asthma
Bronchiectasis
Cystic fibrosis
Alpha 1-antitrypsin deficiency
Chronic bronchitis
Idiopathic pulmonary fibrosis
Lung cancer
Superior vena cava syndrome
Pancoast tumor
Pneumothorax
Mesothelioma
Pleural effusion
Pulmonary embolism
Pulmonary hypertension
Pulmonary edema
Cystic fibrosis: Pathology review
Deep vein thrombosis and pulmonary embolism: Pathology review
Pleural effusion, pneumothorax, hemothorax and atelectasis: Pathology review
Apnea, hypoventilation and pulmonary hypertension: Pathology review
Lung cancer and mesothelioma: Pathology review
Iron deficiency anemia
Beta-thalassemia
Alpha-thalassemia
Sideroblastic anemia
Anemia of chronic disease
Glucose-6-phosphate dehydrogenase (G6PD) deficiency
Autoimmune hemolytic anemia
Sickle cell disease (NORD)
Aplastic anemia
Folate (Vitamin B9) deficiency
Vitamin B12 deficiency
Acute intermittent porphyria
Hemophilia
Hemolytic-uremic syndrome
Thrombotic thrombocytopenic purpura
Immune thrombocytopenia
Von Willebrand disease
Disseminated intravascular coagulation
Heparin-induced thrombocytopenia
Hodgkin lymphoma
Non-Hodgkin lymphoma
Chronic leukemia
Acute leukemia
Myelodysplastic syndromes
Polycythemia vera (NORD)
Myelofibrosis (NORD)
Essential thrombocythemia (NORD)
Mastocytosis (NORD)
Microcytic anemia: Pathology review
Non-hemolytic normocytic anemia: Pathology review
Intrinsic hemolytic normocytic anemia: Pathology review
Extrinsic hemolytic normocytic anemia: Pathology review
Macrocytic anemia: Pathology review
Heme synthesis disorders: Pathology review
Coagulation disorders: Pathology review
Platelet disorders: Pathology review
Mixed platelet and coagulation disorders: Pathology review
Thrombosis syndromes (hypercoagulability): Pathology review
Lymphomas: Pathology review
Leukemias: Pathology review
Plasma cell disorders: Pathology review
Myeloproliferative disorders: Pathology review
Bronchioles and alveoli histology
Trachea and bronchi histology
Lung volumes and capacities
Alveolar surface tension and surfactant
Ventilation
Zones of pulmonary blood flow
Regulation of pulmonary blood flow
Pulmonary shunts
Ventilation-perfusion ratios and V/Q mismatch
Airflow, pressure, and resistance
Gas exchange in the lungs, blood and tissues
Diffusion-limited and perfusion-limited gas exchange
Blood histology
Blood components
Erythropoietin
Ribonucleotide reductase inhibitors
Topoisomerase inhibitors
Platinum containing medications
Anti-tumor antibiotics
Microtubule inhibitors
DNA alkylating medications
Monoclonal antibodies
Antimetabolites for cancer treatment
Antimalarials

Transcript

Watch video only

Topoisomerase inhibitors, as their name implies, are a class of medications that act by blocking an enzyme called topoisomerase.

They are mainly used as anticancer agents that target specific phases of the cell cycle.

An interesting fact about these agents is that they are natural products, meaning they are extracted from roots, plants, or trees.

But first things first.

The cell cycle refers to the events that somatic cells - which includes all of the cells in our bodies except the reproductive cells - go through from the moment they’re formed until the moment they divide into two identical daughter cells.

This cycle varies in length depending on the type of cell.

For rapidly dividing cells, like skin cells, it takes less than a day, whereas for other cells, like liver cells, the cell cycle can last for years.

Now, the cell cycle can be divided into two phases: interphase and mitosis.

Interphase comprises of the G1 phase, during which the cell grows and performs its functions, the S phase, during which DNA is replicated, and the G2 phase, during which the cell grows again before entering mitosis, or the M phase.

Mitosis can be broken down into prophase, metaphase, anaphase, and telophase, during which the replicated DNA divides equally for the two daughter cells, and ends with cytokinesis, which is when the cell membrane actually divides to form the two new cells.

Okay, so during DNA replication, we unzip the double helix with the enzyme DNA helicase and this creates a replication fork, with the two prongs of the fork represented by the two strands that are separated from one another.

Now, as DNA helicase unzips the DNA, the segments of DNA ahead of it start to overwind - meaning, the double helix becomes more tightly wound.

Overwinding of the DNA can slow down replication, so the enzyme DNA topoisomerase works ahead of DNA helicase to loosen up the tight DNA coils.

It achieves this by gently snapping one strand, loosening the overwinding tension, and then patching it back up, tension free.

Okay, so topoisomerase inhibitors are meant to interfere with both types of DNA topoisomerases, called topoisomerase I and II.

Topoisomerase I cuts one of the two strands of the double-stranded DNA during replication, while Topoisomerase II cuts both strands.

If we disable these enzymes, DNA will overwind just like a rubber band, until it tears itself apart, leading to cell death.

Since cancer cells, in general, proliferate faster than healthy cells, they undergo DNA replication more frequently and are more prone to the DNA damage caused by topoisomerase inhibitors.

Alright, now topoisomerase inhibitors are cell cycle-specific, or CCS, agents, and they are the most active during the late S and early G2 phases of the cell cycle.

Okay, let’s start with camptothecins like irinotecan and topotecan, which are isolated from the stems of the Camptotheca tree, also called happy tree, cancer tree, or tree of life.

They bind to and inhibit topoisomerase I and cause DNA damage during replication, leading to cell death.

Irinotecan is a prodrug, meaning that it needs to be metabolized into an active form within the liver before it can produce the desired effect.

In terms of elimination, irinotecan is excreted through bile and feces, while topotecan is excreted through the kidneys, so the dose should be reduced in people with impaired renal function.

Now, irinotecan is used in metastatic colon cancer; and topotecan is used for the treatment of advanced ovarian cancer and for small cell lung cancer.

The two most common side effects are myelosuppression, or depression of the bone marrow function and gastrointestinal problems like diarrhea, which is more common with irinotecan, but in general, these medications have fewer toxicities than most other anticancer agents.

Alright, next we have the podophyllotoxins like etoposide and teniposide, which are derived from mandrake root, or Podophyllum peltatum.

These medications induce DNA breakage through the inhibition of topoisomerase II.

Elimination of teniposide and etoposide is mainly through the kidneys, which again means that the dosage needs to be reduced in people with renal problems.

Moving on to the indications, these agents are used in: solid tumors, particularly in testicular and small cell lung cancer; in leukemia, which is a type of blood cancer primarily affecting stem cells in the bone marrow; and in lymphomas, which usually derive from lymphocytes in the lymph nodes.

Key Takeaways

Topoisomerase inhibitors are a group of medications used in cancer chemotherapy that target the enzyme called DNA topoisomerase I or II, which is involved in DNA replication and transcription.

Topoisomerase inhibitors work by preventing the enzyme from unwinding DNA strands during replication or transcription, which leads to the accumulation of DNA damage and cell death. Examples include irinotecan and topotecan which inhibit topoisomerase I; and etoposide and teniposide which inhibit topoisomerase II.

Topoisomerase inhibitors are used to treat various types of cancer, such as colon cancer, leukemia, ovarian, and small-cell lung cancer. Common side effects of topoisomerase inhibitors include fatigue, gastrointestinal problems like diarrhea, hair loss, anemia, and increased risk of infection. Some patients may also experience more severe side effects, such as cardiac toxicity or secondary malignancies.

Sources

  1. "Katzung & Trevor's Pharmacology Examination and Board Review,12th Edition" McGraw-Hill Education / Medical (2018)
  2. "Rang and Dale's Pharmacology" Elsevier (2019)
  3. "Goodman and Gilman's The Pharmacological Basis of Therapeutics, 13th Edition" McGraw-Hill Education / Medical (2017)
  4. "Nomograms" D. Nicoll , C. Mark Lu, S.J. McPhee (Eds.), Guide to Diagnostic Tests, 7e. McGraw-Hill (2017)
  5. "Overview of hemostasis" J.C. Aster, H. Bunn (Eds.), Pathophysiology of Blood Disorders, 2e. McGraw-Hill. (2016)
  6. "Sensitization of Cancer Cells to Radiation and Topoisomerase I Inhibitor Camptothecin Using Inhibitors of PARP and Other Signaling Molecules" Cancers (2018)
  7. "Formation and biological targets of botanical o-quinones" Food and Chemical Toxicology (2018)